Recombinant Antibodies Network (RAN)

IP: Patent pending
Stage of Development: Preclinical (LI/LO)

The Recombinant Antibody Network (RAN) is a multi-institutional research consortium (member institutions: The University of Toronto, University of California San Francisco and The University of Chicago) created accelerate the identification and development of recombinant antibodies raised against valuable and challenging targets to support drug development and cutting edge biomedical research. The RAN was founded by three ex-Genentech antibody engineers. To date the team has screened and validated over 880 antibodies, some of which are now available for licensing as therapeutics.

OPPORTUNITY

Program	Indication	Target Activity and Differentiating Features	Target Affinity	# Leads
RAN20-1	Multiple Myeloma Chronic Lymphocytic Leukemia	Antibody blocks binding of target ligand to receptor	NM	5
RAN20-2	Checkpoint inhibitor (Hematologic Malignancies, Breast, Glioblastoma, Renal Cancers)	Antibody blocks binding of target ligand to receptor Induces phagocytosis of target tumor cells to a similar extent as clinical-stage antibodies in the same class	NM and Sub NM	2
RAN20-3	Same as RAN20-2	Upstream regulation of TNFa Range of activities: some antibodies bind only to PBMCs and do not impact target ligand binding, others bind to both target ligand and PBMCs	Sub NM	6
RAN20-4	Immune suppressor specific to tumor microenvironment (Leukemia, Glioblastoma, Melanoma, Esophageal, Prostate, Ovarian, Breast Cancers)	ATP-mediated mechanism of binding to target Similar molecules do not have ATP-mediated mechanism of binding, which targets this antibody specifically to the tumor microenvironment	NM (with ATP)	1
RAN20-5	K-Ras Mutations, Pancreatic Cancer	Binds to both full length and cleaved target antigen Functional as an ADC and BiTE	Sub NM	1